Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,174 total articles
Amazon now behaves like two companies in one: a retail engine tightening margins and an AWS business leaning into AI infrastructure spending. Valuation at roughly $2.6 trillion, a P/E around 28, and a 52-week high of $278.56 set a clear upside target. This trade buys the structural AWS tailwind and retail leverage on a disciplined pullback with a $…
Applied Optoelectronics (AAOI) is a small-cap optical supplier benefiting from an accelerating AI datacenter buildout. The stock has already run hard, but a persistent structural shortage in optical transceivers and accelerating customer orders create a path for further gains. This trade idea lays out an entry at $170.00, a stop at $150.00 and a ta…
Chewy is trading near its 52-week low with healthy cash flow, a subscription-heavy revenue base, and oversold technicals. This is a tactical, mid-term swing trade: enter near $18.90, stop at $17.25, and target $28.00 on a 45-trading-day horizon, sized with conviction but limited to a defined risk budget.
PayPay is positioned to convert its large payments footprint into recurring revenue from financial services and advertising. We like a mid-term long with a $4.00 target on a $2.50 entry, stop at $2.00. The trade targets platform monetization + margin expansion over the next 45 trading days, while accepting execution and regulatory risk.
Arlo has shifted revenue mix toward recurring cloud/subscription income and is well positioned to monetize new use cases such as senior monitoring. At current valuation — market cap ~$1.38B and FCF of $64.2M — the risk/reward favors a tactical long while execution continues.
APA trades like a steady cash-generator but hides meaningful optionality from its Suriname offshore program. The stock is cheap on multiple fundamental measures, and a few positive operational or partner milestones could force a re-rate. This trade proposes a controlled long with defined entry, stop and target and a multi-stage horizon for profit-t…
Coeur Mining (CDE) looks oversold relative to its operational leverage and near-term catalysts. This trade idea outlines a disciplined long entry with precise risk controls and clear upside targets over a 45-trading-day swing window.
Super Micro (SMCI) plunged after announcing a $7 billion equity raise to fund component purchases despite reporting $39 billion in AI server orders. The market’s reaction overstates near-term dilution and margin pressure while ignoring the scale of demand and a still-reasonable valuation. This trade idea targets a mid-term rebound as inventory buil…
Adobe plunged after its quarterly release and now trades near its 52-week low. The pullback creates a tactical long opportunity: Adobe trades at a mid-teens PE with $10.3B in free cash flow and a market cap near $88.2B. If the market is over-discounting structural threats from AI and new entrants, Adobe should re-rate higher over the next 45 tradin…
Arvinas is a small-cap biotech that just cleared a major milestone: the first FDA approval for a PROTAC protein degrader with VEPPANU, developed with Pfizer. With a market cap of roughly $457M, an EV of $363M, and meaningful early clinical readouts ahead for LRRK2 degrader ARV-102, we initiate coverage with a Buy. Entry $7.09, target $13.50, stop l…
Melrose looks attractively positioned if the aerospace aftermarket and defense spending stabilize. The market appears to be punishing the stock for headline cyclicality rather than the firm's ability to extract value from industrial assets. This trade recommends a defined-entry long with tight risk control and a mid-term target tied to a modest re-…
Alphabet is uniquely positioned to monetize the next wave of agentic AI while providing diversified upside through stakes in SpaceX and Anthropic. Fundamentals remain solid (market cap ~$4.34T, EPS $13.14, FCF $64.4B), valuation is reasonable for a compounder, and the current technical pullback offers a tactical entry. Actionable trade plan include…
Nano Labs (NA) builds the low-latency networking and compute interfaces that sit between GPUs and the rest of the rack. The shares are microcap, beaten down and highly shorted; with fresh product launches, a North America MoU and insider buying, there is a clear asymmetric trade for disciplined long exposure. This is a tactical swing trade — define…
AbbVie pairs sizable free cash flow and a near-3% yield with credible growth drivers (new launches, obesity program). The setup is constructive: technicals are bullish, valuation on cash flow looks reasonable, and downside is definable. Trade plan: long, entry $225.00, target $260.00, stop $212.00, horizon long term (180 trading days).
Aptiv is a software-and-hardware auto supplier trading at $67.01 with a $14.2B market cap. With improving momentum in ADAS, vehicle electrification, and a healthy free cash flow base of $1.09B, Aptiv offers asymmetric upside to $78.49 while risks (cyclicality, competition, execution) are manageable. Our trade uses a disciplined entry at $67.01, sto…
Nokia is executing on AI-native networking and optical infrastructure initiatives that can re-rate the stock as software and high-value optical sales lift margins. With a $79.7B market cap, recent insider buys, and new AI labs and product announcements, the setup favors a swing-long entry around $13.90 targeting $16.50 with a $12.50 stop — horizon …
FedEx's streamlined express-heavy profile, a $4.1B pro forma cash inflow from the LTL spin-off, and solid free cash flow provide a constructive setup into Q4. We outline a tactical long trade with defined entry, stop and target and a 180-trading-day horizon that captures seasonality and execution upside while respecting macro and competitive risks.
Structure Therapeutics just delivered Phase 2 efficacy that rivals injectables and has the cash to run a Phase 3 program. I upgrade GPCR to my top small-cap obesity pick and present a concrete trade plan with entry at $42.50, stop at $32.00, and a $70.00 target over a 180-trading-day horizon.
SpaceX's IPO has grabbed headlines and valuations, but Amazon's quietly materializing advantages - AWS scale, balance-sheet heft, and a capital-light path to satellite broadband - are underpriced right now. Technicals show fatigue (RSI ~34, MACD negative) after a pullback from the $278 52-week high; valuation metrics (P/E ~28.4, EV/EBITDA ~16.5) le…
Nokia is moving from traditional RAN and IP gear into AI-native networking and data-center solutions. Recent product announcements, an AI Networking Innovation Lab, insider buys near $15.80, and U.S. approvals create a near-term catalyst runway. The stock at $13.88 offers a swing trade opportunity toward the 52-week high, with defined risk controls…
Reddit’s user growth may be slowing, but the business is cash-generative, highly profitable, and richly valued for those metrics. This is a mid-term (45 trading days) long trade that leans on strong margins, recurring AI/data licensing revenue, falling short interest, and constructive technicals. Risk-reward is attractive if you accept a discipline…
Microsoft ($MSFT) offers a high-quality, cash-generative business trading well below recent peaks. Strong free cash flow, a fortress balance sheet, AI-driven growth in Azure and productivity software, and a compressed technical picture make a disciplined buy-the-dip swing trade attractive. Entry, stop and target are provided with clear horizon and …
First Solar is a high-quality solar module maker trading below near-term momentum levels but on solid fundamentals: strong free cash flow, low leverage, and favorable policy catalysts into 2027. This trade recommends a buy on a measured pullback with a clear entry, stop and target for a long-term (180 trading days) position.
Cullinan Therapeutics looks like a classic event-driven biotech swing: clinical-stage programs that could produce binary readthroughs over the next few months, a market capitalization typical of small-cap biotech, and downside that is containable with a tight stop. This trade idea lays out an entry, stop, target, catalysts and the risks that would …
Tempus AI is building a clinical-data and AI platform positioned to monetize precision medicine across oncology, neuroscience and cardiology. The stock trades at ~$48 with a market cap near $8.7B and already high expectations priced in, but expanding pharma partnerships, improving commercial validation and a high short interest create a constructiv…
